Protocol Ledger

NCT05940506 · Phase II · COMPLETED

Phase II Study Evaluating the Efficacy and Safety of KX-826

Interventional Phase II clinical trial protocol NCT05940506 sponsored by Suzhou Kintor Pharmaceutical Inc in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-28 Enrollment: 120 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05940506
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05940506
Protocol FieldVerified Registry Value
NCT IdentifierNCT05940506
Consolidated Lead SponsorSuzhou Kintor Pharmaceutical Inc
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment120 participants (ACTUAL)
Registered Start Date2020-09-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI